Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
REPL Replimune
28.290-0.800-2.75%
Close
02/03 16:00 ET
High
29.470
Open
28.490
Turnover
6.63M
Low
26.264
Pre Close
29.090
Volume
232.87K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Analysts' Top Healthcare Picks: Replimune Group (REPL), Vaccitech Plc (VACC)
Analysts Offer Insights on Healthcare Companies: AmerisourceBergen (ABC), Xenon (XENE) and Replimune Group (REPL)
SG Americas Securities LLC Cuts Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)
SG Americas Securities LLC trimmed its position in shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) by 42.0% during the third quarter, according to its most recent filing with the Securiti
Wall Street Analysts Think Replimune Group, Inc. (REPL) Could Surge 87.88%: Read This Before Placing a Bet
Institutional Investors May Adopt Severe Steps After Replimune Group, Inc.'s (NASDAQ:REPL) Latest 5.3% Drop Adds to a Year Losses
A Look At The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Does the January share price for Replimune Group, Inc. (NASDAQ:REPL) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then d
Replimune Group (NASDAQ:REPL) Now Covered by Analysts at EF Hutton Acquisition Co. I
EF Hutton Acquisition Co. I initiated coverage on shares of Replimune Group (NASDAQ:REPL – Get Rating) in a report issued on Thursday, Benzinga reports. The brokerage issued a buy rating and a $60.00
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
UpgradesFor Algonquin Power & Utilities Corp (NYSE:AQN), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Algonquin Power showed an EPS of $0.11, compared
Replimune Group Initiated at Buy by EF Hutton
Replimune Group Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/05/2023 128.57% EF Hutton → $60 Initiates Coverage On → Buy 12/12/2022 166.67% BMO Capital $40 → $70 Ma
Company Overview
More
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
CEO： Mr. Philip Astley-Sparke
Market： NASDAQ
Listing Date： 07/20/2018
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet